New Business (Life Sciences)

For the purposes of the New York State Life Sciences Research and Development Tax Credit, a “New Business” is an independent entity that has not been a New York taxpayer for more than five years and is not substantially similar in ownership or operation to any current or former New York taxpayer. This classification requires that the business be a newly formed entity rather than an expansion of an existing firm, ensuring that the state’s fiscal incentives are targeted exclusively at fostering the growth of the emerging biotechnology and pharmaceutical startup ecosystem.

The introduction of the Life Sciences Research and Development Tax Credit in 2017 marked a transformative shift in New York’s economic development strategy. Orchestrated by Empire State Development (ESD) and governed by the New York State Department of Taxation and Finance (DTF), the program was designed to counteract the historical trend of life sciences innovation migrating to established hubs in Massachusetts and California. By providing a fully refundable tax credit of up to 20% on qualified research expenditures (QREs), the state effectively provides non-dilutive capital to pre-revenue companies that might otherwise struggle with the high burn rates typical of drug discovery and medical device development. However, the program’s effectiveness relies on a strict definition of what constitutes a “New Business,” a gatekeeping mechanism intended to prevent large, established corporations from reorganizing their internal research departments into new legal entities merely to capture benefits intended for genuine startups. This detailed analysis explores the statutory underpinnings of this definition, the local revenue office guidance that interprets it, and the broader economic implications for the life sciences sector in New York.

The Statutory Framework of the New Business Definition

The eligibility of a taxpayer for the Life Sciences Research and Development Tax Credit is primarily determined by their status as a “Qualified Life Sciences Company,” a term that is inextricably linked to the definition of a “New Business” as set forth in the New York Tax Law. Specifically, Section 43 of the Tax Law serves as the foundational authority for the credit, but it cross-references other sections to define the rigorous standards for new business status.

The Three-Pronged Eligibility Test

Under Section 210-B(1)(f) for corporations (Article 9-A) and Section 606(a)(10) for individuals, partnerships, and estates (Article 22), an entity must satisfy three distinct tests to be certified as a “New Business”. These tests examine the ownership, history, and operational independence of the applicant to ensure that the credit is not being used as a vehicle for tax avoidance by established firms.

The first prong is the Ownership and Control Test. For C-Corporations, the law stipulates that less than 50% of the applicant must be owned or controlled, either directly or indirectly, by another company that is already a taxpayer in New York State. This prevents established pharmaceutical giants already operating in the state from spinning off research labs into “new” companies where they retain a majority stake. Indirect control is often a point of contention during audits, as the Department of Taxation and Finance may look through layers of holding companies to determine the ultimate beneficial owner.

The second prong is the Five-Year Taxpayer Rule. To qualify as a new business, the applicant must not have been a taxpayer in New York State for more than five years. For individual owners, such as sole proprietors or partners, they must not have operated the new business entity in New York for more than five years prior to the application. It is important to note that the five-year clock begins when the entity first becomes subject to New York’s jurisdiction for tax purposes, which typically occurs when it starts “doing business,” employing capital, owning or leasing property, or maintaining an office in the state.

The third prong is the Substantial Similarity Test. This is arguably the most subjective component of the definition. The applicant cannot be “substantially similar in ownership and operation to another company that is, or was previously, a taxpayer in New York State”. This anti-abuse provision is designed to catch “Phoenix” companies—businesses that are dissolved and immediately reconstituted under a different name with the same employees, assets, and research projects to circumvent the five-year limit or restart the three-year credit window.

The Role of Related Persons

In addition to the three-pronged test, Section 43(c)(3) of the Tax Law introduces a “Related Person” disqualification. Empire State Development is prohibited from certifying any entity as a life sciences company if it has been, within the immediately preceding 60 months (five years), a related person to an entity already engaged in scientific research and development or a pre-existing life sciences company.

The definition of a “Related Person” is borrowed from the Internal Revenue Code (IRC) Section 465(b)(3)(C). This expansive federal definition includes family members, entities with common ownership of more than 50%, and certain trust relationships. In the context of the New York R&D credit, this means that if a founder sells a biotech startup and immediately founds a new one with the same primary investors, the second company might be disqualified if the relationship creates an overlap that triggers the 60-month lookback period.

Local State Revenue Office Guidance and Implementation

The Department of Taxation and Finance and Empire State Development provide detailed guidance that clarifies how these statutory requirements are applied in practice. This guidance is often disseminated through Frequently Asked Questions (FAQs), Technical Memoranda (TSB-Ms), and official instructions for tax forms like CT-648.

Operational Meaning of “Doing Business”

For a life sciences startup to understand its five-year window, it must accurately determine when it became a New York taxpayer. Revenue office guidance clarifies that a corporation is subject to tax under Article 9-A if it meets any of several criteria:

• Incorporation: Being a domestic corporation incorporated in New York.
• Physical Presence: Owning or leasing property or maintaining an office in the state.
• Capital Deployment: Employing capital in New York.
• Economic Nexus: Deriving receipts from activity within the state.

For many startups, the “taxpayer” status begins the moment they lease lab space in an incubator like JLABS @ NYC or Alexandria LaunchLabs. This physical presence establishes nexus, starting the five-year clock for “New Business” status. Guidance also clarifies that moving a business from another state into New York does not automatically make it a “New Business” if it fails the five-year test; the clock considers the total time the business has been a taxpayer, regardless of its original location.

Certification and the CFA Process

The local guidance emphasizes that the Life Sciences Research and Development Tax Credit is not a “self-certified” credit. Instead, businesses must first apply to Empire State Development through the Consolidated Funding Application (CFA) portal. During this process, ESD acts as the primary investigator of “New Business” status.

The application requires detailed disclosures regarding:

1. Ownership Structure: A cap table or list of all owners with 5% or more interest.
2. Corporate History: Documentation of when the company first established a presence in New York.
3. Operational Details: A description of research activities to ensure they fall within the statutory definition of life sciences.

Upon approval, ESD issues a “Certificate of Tax Credit,” which is the only document that allows a business to actually claim the credit on its tax return. Revenue office guidance is explicit: without this certificate, any R&D credit claimed on Form CT-648 or IT-648 will be summarily denied.

Interaction with the Metropolitan Transportation Authority (MTA) Surcharge

An important nuance provided in the Article 9-A instructions is that the Life Sciences Research and Development Tax Credit cannot be used to reduce the MTA surcharge. While the credit can reduce the business’s franchise tax to the fixed dollar minimum, it has no impact on the additional tax imposed on businesses operating within the Metropolitan Commuter Transportation District (MCTD). This is a critical distinction for the many biotechnology firms located in Manhattan and the surrounding boroughs.

Qualified Life Sciences Fields and Scientific Scope

To be a “New Business” in the context of this credit, the entity must be “principally engaged” in a qualified life sciences field. This means that the majority of the entity’s efforts must be devoted to the various stages of research, development, technology transfer, and commercialization of life sciences. The statutory list of qualified fields is intentionally expansive to reflect the interdisciplinary nature of modern biotechnology.

Qualified Life Sciences Sector	Scope and Application
Academic Medical Centers	Collaborative research between universities and clinical environments.
Agricultural Biotechnology	Innovation in crop yields, disease resistance, and bio-fuels.
Biogenerics & Biopharmaceuticals	Development of large-molecule drugs and biosimilars.
Bioinformatics	Computational biology, data mining, and genomic sequencing analysis.
Biomedical Engineering	Integration of engineering principles with biological systems for healthcare.
Chemical Synthesis	Novel methods for creating molecular compounds for therapeutic use.
Genomics & Proteomics	Study of whole genomes and protein structures to identify disease markers.
Medical Devices & Diagnostics	Hardware and software used for diagnosing, treating, or monitoring conditions.
Medical Nanotechnology	Utilizing nanoscale materials for drug delivery or surgical precision.
Marine Biology	Researching marine organisms for potential pharmaceutical or industrial use.

The guidance provided by ESD clarifies that simply being a service provider to these industries is not enough. For example, a law firm specializing in biotech patents or a marketing agency for pharmaceutical companies would not qualify, even if 100% of their clients are in the life sciences sector. The entity itself must be the one performing the R&D or commercialization of the technology.

Comparative Analysis of Qualified Research Expenditures (QREs)

The calculation of the tax credit for a “New Business” is based on Qualified Research Expenditures as defined in Section 41(b) of the Internal Revenue Code, but with significant New York-specific modifications. Understanding these differences is paramount for accurate tax planning and preventing audit adjustments.

In-House Research vs. Contract Research

The most striking difference between the federal R&D tax credit and the New York Life Sciences credit is the treatment of contract research. At the federal level, companies can typically include 65% of payments made to third-party contractors as QREs. However, the New York State Life Sciences program explicitly excludes all contract research expenses.

This policy choice is designed to ensure that the “New Business” is building its own intellectual and physical infrastructure within New York State. By excluding contractors, the state effectively incentivizes startups to hire full-time employees and invest in their own laboratory equipment rather than outsourcing the scientific heavy lifting to out-of-state “Contract Research Organizations” (CROs).

Eligible Expenditure Categories

For a “New Business” to maximize its credit, it must focus on three primary categories of in-state spending:

1. Wages: Salaries paid to employees for performing qualified services, which include not only the direct performance of research but also the direct supervision or direct support of such research.
2. Supplies: Tangible property (excluding land or improvements to real property) that is consumed during the R&D process. This typically includes lab reagents, chemicals, and disposable laboratory equipment.
3. Computer Leases/Rentals: Costs for cloud computing services, such as AWS or Google Cloud, provided the computing power is used directly for qualified research activities like bioinformatics or molecular modeling.

Revenue office guidance emphasizes that these expenditures must be “incurred in New York State”. This means that if a “New Business” has a laboratory in Buffalo and another in New Jersey, only the wages paid to the Buffalo-based researchers and the supplies consumed in the Buffalo lab can be used to calculate the New York credit.

The Financial Mechanics of the Credit: Rates, Caps, and Refundability

The Life Sciences Research and Development Tax Credit is structured to be particularly advantageous for the smallest startups, providing them with a higher rate of return on their R&D investment.

Tiered Credit Rates

The credit amount is determined by a simple headcount-based tier system:

• 20% Credit Rate: For a “New Business” that employs fewer than 10 persons during the taxable year.
• 15% Credit Rate: For a “New Business” that employs 10 or more persons during the taxable year.

Employment is determined by calculating the average number of full-time employees (excluding general executive officers) on the last day of each quarter (March 31, June 30, September 30, and December 31). If a company starts the year with 8 employees and grows to 12 by the fourth quarter, its average would likely exceed 10, dropping its credit rate from 20% to 15% for that year. Conversely, a company that downsizes might see its rate increase in the following year.

Annual and Lifetime Caps

To manage the state’s fiscal exposure, the program includes several layers of caps:

• Individual Annual Cap: No single company or combined group can receive more than $500,000 in credits in a single year.
• Individual Lifetime Cap: Participation is limited to three consecutive taxable years, resulting in a maximum possible lifetime benefit of $1.5 million.
• Statewide Aggregate Cap: New York allocates $10 million annually for the program.

The statewide cap is managed through the application process. Credits are awarded on a first-come, first-served basis according to the date of application with ESD. If the total applications exceed the $10 million limit in a given year, the excess applications are treated as having been filed on the first day of the subsequent year.

Refundability: The Lifecycle of a Startup

For a “New Business” that has not yet reached profitability—a common state for biotechs for a decade or more—the refundability of the credit is its most critical feature. While the credit first reduces the entity’s tax liability to the “fixed dollar minimum tax” (which can be as low as $25 for very small firms), any remaining credit is treated as an overpayment.

Taxpayers can elect to have this overpayment refunded in cash or applied as a credit toward the following year’s estimated tax. For a cash-strapped startup, the refund serves as a vital non-dilutive injection of liquidity, allowing them to extend their “runway” and delay the need for another round of venture capital funding.

Detailed Multi-Year Example: GenePath Diagnostics Inc.

To illustrate the interplay of these rules, we can track “GenePath Diagnostics Inc.,” a fictional bioinformatics startup based in Syracuse, New York.

Year 1: Qualifying as a New Business

In 2023, GenePath is incorporated by two PhD researchers. They lease a small office in a Syracuse technology incubator and hire two additional software engineers.

• Status: Certified as a “New Business” and a “Qualified Life Sciences Company.”
• Headcount: 4 employees (Rate = 20%).
• NY QREs: $600,000 in wages + $50,000 in cloud computing costs = $650,000.
• Calculation: $650,000 x 20% = 130,000.
• Tax Liability: $25 (Fixed dollar minimum).
• Result: GenePath receives a refund of $129,975.

Year 2: Scaling the Workforce

In 2024, the company receives a Series A investment and expands its team to 12 employees to accelerate product development.

• Status: Remains a “New Business” (Year 2 of 3).
• Headcount: 12 employees (Rate = 15%).
• NY QREs: $2,000,000 in wages + $100,000 in supplies + $500,000 in contract research.
• Adjustment: Contract research is excluded. Total NY QREs = $2,100,000.
• Calculation: $2,100,000 x 15% = 315,000.
• Result: Since $315,000 < 500,000, the full amount is awarded as a credit/refund.

Year 3: Reaching the Annual Cap

In 2025, GenePath has 20 employees and significantly increases its R&D spending.

• Status: Final year of eligibility (Year 3 of 3).
• Headcount: 20 employees (Rate = 15%).
• NY QREs: $3,500,000 in wages and supplies.
• Calculation: $3,500,000 x 15% = 525,000.
• Adjustment: The credit is capped at $500,000 per year.
• Result: GenePath receives a $500,000 credit/refund.

Over three years, this “New Business” has received a total of $945,000 in state funding, significantly aiding its transition from a garage startup to a viable commercial entity.

Sector Statistics and Program Impact

Data from the Life Science Initiative Annual Reports (2023 and 2024) demonstrates the profound impact that the R&D tax credit and broader state initiatives have had on the regional economy. By lowering the cost of innovation for new businesses, New York has successfully positioned itself as a global leader in the life sciences sector.

Impact Category	Cumulative Program Achievement (As of Oct 2024)
Total ESD Grant Commitments	$236.63 million
Leveraged External Investment	$4.1 billion
Qualified In-State R&D Spending	$163.7 million (from 89 awardees)
New Companies Formed/Retained	60
New Jobs Created (Grant Programs)	674
Net New Jobs (Excelsior Tax Credits)	271
New Patents Filed/Granted	391
Total NYC Laboratory Space	>3.8 million square feet

Source: Life Science Initiative Annual Report 2024.

The statistics reveal a 7.7% increase in life science jobs and a staggering 33% growth in the number of life science companies in the state since the initiative’s 2017 inception. Furthermore, the life science job growth rate in New York has been over four times greater than the state’s overall private sector growth rate, suggesting that the “New Business” incentives are successfully attracting talent to high-value, high-skill industries.

Strategic Insights: The “Similarity” and “Ownership” Hurdles

For founders and investors, the most significant risk to claiming the Life Sciences R&D credit lies in the subjective interpretation of the “New Business” status by state auditors.

Navigating Substantial Similarity

The “Substantial Similarity” test is a qualitative analysis that goes beyond the cap table. If a new company hires the same research director, uses the same lab benches, and pursues the same therapeutic target as a defunct predecessor, the state may argue that it is merely a continuation of an old business. To mitigate this risk, founders should be prepared to demonstrate a “clean break” from previous entities, highlighting differences in:

• Intellectual Property: New patent filings or licensed technologies that differ from the predecessor.
• Target Markets: A shift in focus from oncology to rare diseases, for example.
• Capitalization: A new lead investor or a significantly different funding structure.

Venture Capital and Control

A second-order insight involves the impact of Venture Capital (VC). If a VC firm is a New York taxpayer—as many major firms are—and they acquire a 51% stake in a startup, that startup may immediately lose its “New Business” status because more than 50% of it is now “owned or controlled” by another New York taxpayer. This can create a perverse incentive for founders to resist majority-stake investments from local firms, potentially driving them to seek capital from out-of-state or international investors to preserve their tax credits.

Administrative Compliance: Form CT-648 and Form IT-648

Claiming the credit requires meticulous adherence to filing procedures as outlined in the Form CT-648 instructions.

Line-by-Line Requirements for Corporations

• Certificate Information: The taxpayer must enter the amount of credit listed on the ESD certificate. If the certificate shows more than $500,000, the taxpayer must manually cap the claim at $500,000.
• Combined Groups (Schedule B): In cases where multiple members of a combined group are qualified life sciences companies, the group as a whole is still limited to a single $500,000 cap.
• Partnership Information (Schedule C): If the taxpayer is a corporate partner receiving a share of the credit from a partnership, they must provide the partnership’s EIN and the exact amount of the credit passed through.

Ordering of Credits

The Life Sciences Research and Development Tax Credit must be applied in a specific order against other business incentives. According to Form CT-600-I, certain credits must be taken before the life sciences credit. If the taxpayer fails to follow this order, it can lead to automated processing delays or the miscalculation of the refundable portion of the credit.

Final Thoughts: Fostering a Sustained Innovation Ecosystem

The New York Life Sciences Research and Development Tax Credit is more than just a fiscal incentive; it is a structural mechanism designed to lower the barrier to scientific entry and anchor the next generation of medical breakthroughs within the state. By defining “New Business” through the rigorous lens of Section 210-B(1)(f), New York ensures that its resources are directed toward the most agile and innovative segment of the economy—the independent startup.

The credit’s tiered rates and full refundability recognize the unique financial lifecycle of life sciences firms, providing cash flow precisely when it is most needed during the pre-revenue R&D phase. However, the program’s success is contingent upon the applicant’s ability to navigate the complex regulatory environment of Empire State Development and the Department of Taxation and Finance. With the current program scheduled to accept applications for expenses through 2027, “New Businesses” in the life sciences sector have a significant, albeit time-limited, opportunity to leverage state support to transform their research into reality. For the visionary founder, understanding the nuances of “New Business” status is not just a matter of tax compliance—it is a strategic imperative for long-term growth and scientific success in the Empire State.